Cited by 2,162Meta-analysis and systematic reviewsStatistical Methods in EpidemiologyCancer Diagnosis and Treatment

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

McShane, Lisa M., Altman, Douglas G., Sauerbrei, Willi, Taube, Sheila E., Gion, Massimo, Clark, Gary M.·2005·JNCI: Journal of the National Cancer Institute

DOI 10.1093/jnci/dji237

Open this paper in CoChat — free account

Abstract

Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.

Integrity signals

Registry

Crossref · 10.1093/jnci/dji237

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citation
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citation
Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citation
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citation
The Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129

Show all 46 references

Sorted by citations

Items 901–1,000 of 1,003

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
Mercogliano, M. F., Inurrigarro, G., Martino, M. D., Venturutti, L., Rivas, M. A., Russo, R. I. C., Proietti, C. J., Fernández, E. A., Frahm, I., Barchuk, S., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3897-x · Cited by 35
Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer
Kawaguchi, T., Yan, L., Qi, Q., Peng, X., Edge, S. B., Young, J. S., Yao, S., Liu, S., Otsuji, E., & Takabe, K. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6859-x · Cited by 35
Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis
Dabir, P. D., Bruggeling, C. E., van der Post, R. S., Dutilh, B. E., Hoogerbrugge, N., Ligtenberg, M. J. L., Boleij, A., & Nagtegaal, I. D. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0538-7 · Cited by 35
Predicting Radiation Resistance in Breast Cancer with Expression Status of Phosphorylated S6K1
Choi, J., Yoon, Y., Kim, N., Park, C. S., Seol, H., Park, I., Kim, H.-A., Noh, W., Kim, J., & Seong, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-57496-8 · Cited by 36
PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications
Jørgensen, C. L. T., Larsson, A.-M., Forsare, C., Aaltonen, K. E., Jansson, S., Bradshaw, R., Bendahl, P., & Rydén, L. (2021) · Cancers · doi:10.3390/cancers13071592 · Cited by 32
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation
Costentin, C. E., Piñero, F., Degroote, H., Notarpaolo, A., Boin, I. D. F. S. F., Boudjéma, K., Baccaro, C., Podestá, L. G., Bachellier, P., Ettorre, G. M., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100445 · Cited by 35
TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis
Perkins, S. M., Bales, C. L., Vladislav, I. T., Althouse, S. K., Miller, K. D., Sandusky, G. E., Badve, S., & Nakshatri, H. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3492-2 · Cited by 35
Single measurement of hemoglobin predicts outcome of HCC patients
Finkelmeier, F., Bettinger, D., Köberle, V., Schultheiß, M., Zeuzem, S., Kronenberger, B., Piiper, A., & Waidmann, O. (2013) · Medical Oncology · doi:10.1007/s12032-013-0806-2 · Cited by 36
High expression of 90K (Mac‐2 BP) is associated with poor survival in node‐negative breast cancer patients not receiving adjuvant systemic therapies
Tinari, N., Lattanzio, R., Querzoli, P., Natoli, C., Grassadonia, A., Alberti, S., Hubalek, M., Reimer, D., Nenci, I., Bruzzi, P., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23970 · Cited by 35
The clinical use of biomarkers as prognostic factors in Ewing sarcoma
van Maldegem, A. M., Hogendoorn, P. C. W., & Hassan, A. B. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-7 · Cited by 35
Contrasted Outcomes to Gefitinib on Tumoral IGF1R Expression in Head and Neck Cancer Patients Receiving Postoperative Chemoradiation (GORTEC Trial 2004-02)
Thariat, J., Bensadoun, R., Étienne-Grimaldi, M.-C., Grall, D., Penault-Llorca, F. M., Dassonville, O., Bertucci, F., Cayre, A., Raucourt, D. D., Geoffrois, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1518 · Cited by 35
Aberrations of ERBB2 and TOP2A genes in breast cancer
Nielsen, K. V., Müller, S., Möller, S., Schönau, A., Balslev, E., Knoop, A. S., & Ejlertsen, B. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.11.001 · Cited by 34
A Prognostic Gene Expression Profile That Predicts Circulating Tumor Cell Presence in Breast Cancer Patients
Molloy, T. J., Roepman, P., Naume, B., & Veer, L. J. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032426 · Cited by 34
Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy
Woolston, C. M., Deen, S., Al‐Attar, A., Shehata, M., Chan, S. Y. T., & Martin, S. G. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.07.008 · Cited by 34
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration
Janssens, A. C. J. W., Ioannidis, J. P. A., Bedrosian, S. R., Boffetta, P., Dolan, S. M., Dowling, N. F., Fortier, I., Freedman, A. N., Grimshaw, J., Gulcher, J. R., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.27 · Cited by 33
Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
Page, C. L., Huntsman, D. D., Provencher, D. M., & Mes‐Masson, A. (2010) · Cancers · doi:10.3390/cancers2020913 · Cited by 33
'Toxgnostics': an unmet need in cancer medicine
Church, D. N., Kerr, R. S., Domingo, E., Rosmarin, D., Palles, C., Maskell, K. F., Tomlinson, I. P. M., & Kerr, D. J. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3729 · Cited by 34
Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials
Johnson, D. R., & Galanis, E. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0279-z · Cited by 34
An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer
Sánchez‐Navarro, I., Gámez‐Pozo, A., Pinto, Á., Hardisson, D., Madero, R., López, R., José, B. S., Zamora, P. M., Redondo, A., Feliú, J., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-336 · Cited by 34
High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes
Anderson, J. C., Willey, C. D., Mehta, A., Welaya, K. Y., Chen, D., Duarte, C. W., Ghatalia, P., Arafat, W. O., Madan, A., Sudarshan, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139267 · Cited by 34
The Prediction of Clinical Outcome in Hepatocellular Carcinoma Based on a Six-Gene Metastasis Signature
Yuan, S., Wang, J., Yang, Y., Zhang, J., Liu, H., Xiao, J., Xu, Q., Huang, X., Xiang, B., Zhu, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0395 · Cited by 34
E2F1-regulated long non-coding RNA RAD51-AS1 promotes cell cycle progression, inhibits apoptosis and predicts poor prognosis in epithelial ovarian cancer
Zhang, X., Liu, G., Qiu, J., Zhang, N., Ding, J., & Hua, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-04736-z · Cited by 34
Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells
Mjønes, P., Nordrum, I. S., Sørdal, Ø. F., Sagatun, L., Fossmark, R., Sandvik, A. K., & Waldum, H. L. (2017) · Hormones and Cancer · doi:10.1007/s12672-017-0311-8 · Cited by 34
Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer
Uhr, K., Sieuwerts, A. M., de Weerd, V., Smid, M., Hammerl, D., Foekens, J. A., & Martens, J. W. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27987-w · Cited by 34
Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer
Carter, J. H., Deddens, J. A., Mueller, G., Lewis, T. G., Dooley, M. K., Robillard, M. C., Frydl, M., Duvall, L. R., Pemberton, J. O., & Douglass, L. E. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0191-x · Cited by 34
Polymorphic Variants in NR 1I3 and UGT 2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study
Arbitrio, M., Scionti, F., Altomare, E., Martino, M. T. D., Agapito, G., Galeano, T., Staropoli, N., Iuliano, E., Grillone, F., Fabiani, F., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1391 · Cited by 34
PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma
Billon, E., Finetti, P., Bertucci, A., Niccoli, P., Birnbaum, D., Mamessier, É., & Bertucci, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655362 · Cited by 34
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
Nissen, N. I., Kehlet, S. N., Boisen, M. K., Liljefors, M., Jensen, C., Johansen, A. Z., Johansen, J. S., Erler, J. T., Karsdal, M. A., Mortensen, J. H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79608-0 · Cited by 35
STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement
Gallo, V., Egger, M., McCormack, V., Farmer, P. B., Ioannidis, J. P. A., Kirsch‐Volders, M., Matullo, G., Phillips, D. H., Schoket, B., Strömberg, U., et al. (2011) · Mutagenesis · doi:10.1093/mutage/ger039 · Cited by 36
Systematic review of statistical methods used in molecular marker studies in cancer
Vickers, A. J., Jang, K. S., Sargent, D. J., Lilja, H. G., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23365 · Cited by 34
Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy
Abdel-Fatah, T. M. A., Albarakati, N., Bowell, L., Agarwal, D., Moseley, P. M., Hawkes, C., Ball, G., Chan, S. Y. T., Ellis, I. O., & Madhusudan, S. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2769-6 · Cited by 34
Selective In Vivo Imaging of Syngeneic, Spontaneous, and Xenograft Tumors Using a Novel Tumor Cell–Specific Hsp70 Peptide-Based Probe
Stangl, S., Varga, J., Freysoldt, B., Trajkovic‐Arsic, M., Siveke, J. T., Greten, F. R., Ntziachristos, V., & Multhoff, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0413 · Cited by 34
Co-Expression of TWIST1 and ZEB2 in Oral Squamous Cell Carcinoma Is Associated with Poor Survival
Kong, Y. H., Zanaruddin, S. N. S., Lau, S. H., Ramanathan, A., Kallarakkal, T. G., Vincent–Chong, V. K., Mustafa, W. M. W., Abraham, M. T., Rahman, Z. A. A., Zain, R. B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134045 · Cited by 35
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
Fountzilas, G., Dafni, U. G., Bobos, M., Kotoula, V., Batistatou, A. K., Xanthakis, I., PAPADIMITRIOU, C. A., Kostopoulos, I. S., Κoletsa, T., Tsolaki, E., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-163 · Cited by 33
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
Xenidis, N., Perraki, M., Apostolaki, S., Agelaki, S., Kalbakis, K., Vardakis, N., Kalykaki, A., Xyrafas, A., Kakolyris, S., Mavroudis, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.597 · Cited by 33
MTHFR Glu429Ala and ERCC5 His46His Polymorphisms Are Associated with Prognosis in Colorectal Cancer Patients: Analysis of Two Independent Cohorts from Newfoundland
Negandhi, A. A., Hyde, A. J., Dicks, E. L., Pollett, W. G., Younghusband, B., Parfrey, P. S., Green, R. C., & Savas, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061469 · Cited by 33
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab
Razis, E. D., Pentheroudakis, G. E., Rigakos, G., Bobos, M., Kouvatseas, G., Tzaida, O., Makatsoris, T., Papakostas, P., Bai, M. C., GOUSSIA, A. C., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1626-2 · Cited by 36
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
Witzel, I., Loibl, S., von Minckwitz, G., Eidtmann, H., Fehm, T. N., Khandan, F., Schmatloch, S., Hauschild, M., Bischoff, J., Fasching, P. A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.353 · Cited by 33
Circulating Tumor Cells and Plasma DNA Analysis in Patients with Indeterminate Early or Metastatic Breast Cancer
Shaw, J., Brown, J., Coombes, R. C., Jacob, J., Payne, R., Lee, B., Page, K., Hava, N., & Stebbing, J. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.10.118 · Cited by 33
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer
Klintman, M., Strand, C., Ahlin, C., Beglerbegovic, S., Fjällskog, M.-L., Grabau, D. A., Gudlaugsson, E. G., Janssen, E. A. M., Lövgren, K., Skaland, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081902 · Cited by 33
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
Park, Y. H., Shin, H., Jung, H. H., Choi, Y., Ahn, T., Park, K., Lee, A., Do, I., Kim, J., Ahn, J. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5184 · Cited by 36
Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers
Arora, A., Abdel-Fatah, T. M. A., Agarwal, D., Doherty, R. E., Croteau, D. L., Moseley, P. M., Hameed, K., Green, A. R., Aleskandarany, M. A., Rakha, E. A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv163 · Cited by 33
The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival
Kilvaer, T. K., Paulsen, E., Rakaee, M., Al‐Saad, S., Maurseth, R. J., Al-Shibli, K. I., Bremnes, R. M., Busund, L., & Dønnem, T. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.92 · Cited by 33
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Ferrer, I., Quintanal-Villalonga, À., Molina‐Pinelo, S., García-Heredia, J. M., Pérez, M., Suárez, R. A., Ponce-Aix, S., Paz-Ares, L. G., & Carnero, A. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0871-7 · Cited by 33
ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells
Lei, X., Deng, L., Liu, D., Liao, S., Dai, H., Li, J., Rong, J., Wang, Z., Huang, G., Tang, C. W., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4535 · Cited by 33
Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
Larsson, A.-M., Bendahl, P., Aaltonen, K. E., Jansson, S., Forsare, C., Bergqvist, M., Jørgensen, C. L. T., & Rydén, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-61416-1 · Cited by 33
Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer
Guo, Y., Gabola, M., Lattanzio, R., Paul, C., Pinet, V., Tang, R., Turali, H., Bremond, J., Longobardi, C., Maurizy, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131517 · Cited by 33
Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer
Abdel-Fatah, T. M. A., Perry, C., Moseley, P. M., Johnson, K., Arora, A., Chan, S. Y. T., Ellis, I. O., & Madhusudan, S. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2820-7 · Cited by 33
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
Egerod, F. L., Bartels, A., Fristrup, N., Borre, M., Orntoft, T. F., Oleksiewicz, M. B., Brünner, N., & Dyrskjøt, L. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-385 · Cited by 33
TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome
Aleskandarany, M. A., Negm, O. H., Rakha, E. A., Ahmed, M. A. H., Nolan, C. C., Ball, G., Caldas, C., Green, A. R., Tighe, P. J., & Ellis, I. O. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2249-4 · Cited by 33
Estrogen-Dependent Prognostic Significance of Cyclooxygenase-2 Expression in Early-Stage Invasive Breast Cancers Treated With Breast-Conserving Surgery and Radiation
Haffty, B. G., Yang, Q., Moran, M. S., Tan, A. R., & Reiß, M. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.063 · Cited by 33
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers
Yue, Y., Astvatsaturyan, K., Cui, X., Zhang, X., Fraass, B. A., & Bose, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149661 · Cited by 33
Prognostic significance of α‐ and β2‐adrenoceptor gene expression in breast cancer patients
Rivero, E. M., Martinez, L. M., Bruque, C. D., Gargiulo, L., Bruzzone, A., & Lüthy, I. A. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14030 · Cited by 34
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene
van Kempen, L. C. L., Redpath, M., Elchebly, M., Klein, K. O., Papadakis, A. I., Wilmott, J. S., Scolyer, R. A., Edqvist, P.-H., Pontén, F., Schadendorf, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai9188 · Cited by 29
Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer
Forse, C. L., Agarwal, S., Pinnaduwage, D., Gertler, F. B., Condeelis, J. S., Lin, J., Xue, X., Johung, K. L., Mulligan, A. M., Rohan, T. E., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1468-6 · Cited by 32
Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma
Mehta, A., Sinha, R., Azam, S., Batra, U., & Doval, D. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.139450 · Cited by 32
Utility or futility of prognostic scoring systems for colorectal liver metastases in an era of advanced multimodal therapy
Grégoire, É., Hoti, E., Gorden, D. L., la Serna, S. C. D., Pascal, G., & Azoulay, D. (2010) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.03.009 · Cited by 32
Extracapsular Extension of Pelvic Lymph Node Metastasis is an Independent Prognostic Factor in Bladder Cancer: A Systematic Review and Meta-analysis
Ahn, T. S., Kim, H. S., Jeong, C. W., Kwak, C. H., Kim, H. H., & Ku, J. H. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4359-1 · Cited by 32
The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer
Woolston, C. M., Zhang, L., Storr, S. J., Al‐Attar, A., Shehata, M., Ellis, I. O., Chan, S. Y. T., & Martin, S. G. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.60 · Cited by 32
Metastatic Spread Emerging From Liver Metastases of Colorectal Cancer
Rahbari, N. N., Bork, U., Schölch, S., Reißfelder, C., Thorlund, K., Betzler, A. M., Kahlert, C., Schneider, M. A., Ulrich, A. B., Büchler, M. W., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001341 · Cited by 32
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma
Petrushnko, W., Gundara, J. S., de Reuver, P. R., O’Grady, G., Samra, J. S., & Mittal, A. (2016) · HPB · doi:10.1016/j.hpb.2016.05.004 · Cited by 33
TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study
Terashima, M., for the ACTS-GC Group, Ichikawa, W., Ochiai, A., Kitada, K., Kurahashi, I., Sakuramoto, S., Katai, H., Sano, T., Imamura, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15895 · Cited by 32
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
Absmaier, M., Napieralski, R., Schuster, T., Aubele, M. M., Walch, A. K., Magdolen, V., Dorn, J., Groß, E., Harbeck, N., Noske, A., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4241 · Cited by 32
The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer
Guo, B., & Lu, W.-Q. (2018) · Oncotarget · doi:10.18632/oncotarget.25702 · Cited by 32
Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis
Kidd, M. S., Drozdov, I. A., Matar, S., Gurunlian, N., Ferranti, N. J., Malczewska, A., Bennett, P., Bodei, L., & Modlin, I. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218592 · Cited by 33
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
Jensen, M., Lænkholm, A., Balslev, E., Buckingham, W., Ferree, S., Glavicic, V., Jensen, J. D., Knoop, A. S., Mouridsen, H. T., Nielsen, D. L., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0148-0 · Cited by 32
Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer
Nguyen, D., Yu, J. S., Reinhold, W. C., & Yang, S. X. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.7213 · Cited by 32
The molecular profile of mucosal melanoma
Mikkelsen, L. H., Maag, E., Andersen, M. K., Kruhøffer, M., Larsen, A., Melchior, L. C., Toft, P. B., von Buchwald, C., Wadt, K., & Heegaard, S. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000686 · Cited by 33
Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients
Alço, G., Bozdoğan, A., Selamoğlu, D., Pilancı, K. N., Tuzlalı, S., Ordu, Ç., İğdem, Ş., Okkan, S., Dinçer, M., Demir, G., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.2852 · Cited by 32
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
Yao, S., Sucheston, L. E., Zhao, H., Barlow, W. E., Zirpoli, G., Liu, S., Moore, H. C. F., Budd, G. T., Hershman, D. L., Davis, W., et al. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.32 · Cited by 32
Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer
Aaltonen, K. E., Rosendahl, A. H., Olsson, H., Malmström, P., Hartman, L. W., & Fernö, M. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-794 · Cited by 32
Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations.
Grivas, P. D., Tzelepi, V., Sotiropoulou‐Bonikou, G., Kefalopoulou, Z. M., Papavassiliou, A. G., & Kalofonos, H. P. (2009) · PubMed Central · doi:10.3233/clo-2009-0467 · Cited by 32
Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
Magnussen, S. N., Rikardsen, O., Hadler‐Olsen, E., Uhlin‐Hansen, L., Steigen, S. E., & Svineng, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101895 · Cited by 32
Lysine‐specific demethylase‐1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer
Kosumi, K., Baba, Y., Sakamoto, A., Ishimoto, T., Harada, K., Nakamura, K., Kurashige, J., Hiyoshi, Y., Iwatsuki, M., Iwagami, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29714 · Cited by 33
Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study
Li, Q., Zhi, X., Zhou, J., Tao, R., Zhang, J., Chen, P., Røe, O. D., Sun, L., & Ma, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9128 · Cited by 32
Breast
(2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7_32 · Cited by 32
Micrometastatic disease in breast cancer: Clinical implications
Ignatiadis, M., Georgoulias, V., & Mavroudis, D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.033 · Cited by 32
Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development
Kelloff, G. J., & Sigman, C. C. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2154 · Cited by 32
Limits to forecasting in personalized medicine: An overview
Ioannidis, J. P. A. (2009) · International Journal of Forecasting · doi:10.1016/j.ijforecast.2009.05.003 · Cited by 31
Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen
Winder, T. L., Giamas, G., Wilson, P. M., Zhang, W., Yang, D., Bohanes, P. O., Ning, Y., Gerger, A., Stebbing, J., & Lenz, H. J. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.8 · Cited by 31
Reporting the Accuracy of Diagnostic Tests: The STARD Initiative 10 Years On
Ochodo, E., & Bossuyt, P. M. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206516 · Cited by 31
High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients
Ilm, K., Kemmner, W., Osterland, M., Burock, S., Koch, G., Herrmann, P., Schlag, P. M., & Stein, U. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0316-2 · Cited by 31
Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study
Cho, E. J., Lee, J., Yoo, J., Choi, W.-M., Lee, M. J., Cho, Y., Lee, Y. B., Lee, Y. B., Kwon, J. H., Yu, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3443 · Cited by 31
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
Azim, H. A., Kassem, L. M. H., Treilleux, I., Wang, Q., Enein, M. A. E., Anis, S. E., & Bachelot, T. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.01.001 · Cited by 32
Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC
Petersen, L. F., Klimowicz, A. C., Otsuka, S., Elegbede, A. A., Petrillo, S. K., Williamson, T. S., Williamson, C. T., Konno, M., Lees‐Miller, S. P., Hao, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16215 · Cited by 32
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS)
Kim, H., Yu, S. J., Yeo, I., Cho, Y. Y., Lee, D. H., Cho, Y., Cho, E. J., Lee, J., Kim, Y. J., Lee, S., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.066704 · Cited by 31
A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Yang, Q., Zhang, M., Zou, X., Liu, Y.-P., You, R., Yu, T., Jiang, R., Zhang, Y.-N., Cao, J.-Y., Hong, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1963 · Cited by 31
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer
Szarvas, T., Sevcenco, S., Módos, O., Keresztes, D., Nyírády, P., Kubik, A., Romics, M., Kovalszky, I., Reis, H., Hadaschik, B. A., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.03.010 · Cited by 31
Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review
Pinart, M., Kunath, F., Lieb, V., Tsaur, I., Wullich, B., & Schmidt, S. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2574-2 · Cited by 31
Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization
Fako, V. E., Martin, S. P., Pomyen, Y., Budhu, A., Chaisaingmongkol, J., Heinrich, S., Lee, J. M., Ng, I. O., Cheung, T. T., Wei, X., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.39534 · Cited by 31
Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables
Rubio, A. I., Yufera, J. C., de la Morena, P., Sánchez, A. F., Manzano, E. N., Garre, E. G., Martínez, E. G., Zafra, G. M., Cánovas, M. S., Torralba, E. G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53606-3 · Cited by 31
Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294
McGee, K. P., Hwang, K., Sullivan, D. C., Kurhanewicz, J. V., Hu, Y., Wang, J., Li, W., Debbins, J. P., Paulson, E. S., Olsen, J. R., et al. (2021) · Medical Physics · doi:10.1002/mp.14884 · Cited by 31
Regulation of TRIB3 mRNA and Protein in Breast Cancer
Wennemers, M., Bussink, J., van den Beucken, T., Sweep, F. C. G. J., & Span, P. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049439 · Cited by 32
High Nuclear Hypoxia-Inducible Factor 1 Alpha Expression Is a Predictor of Distant Recurrence in Patients With Resected Pancreatic Adenocarcinoma
Colbert, L. E., Fisher, S. B., Balcı, S., Saka, B., Chen, Z., Kim, S., El‐Rayes, B. F., Adsay, V. N., Maithel, S. K., Landry, J. C., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.11.004 · Cited by 31
Gene expression profiling and prediction of clinical outcome in ovarian cancer
Sabatier, R., Finetti, P., Cervera, N., Birnbaum, D., & Bertucci, F. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.007 · Cited by 31
Occult Tumor Burden Predicts Disease Recurrence in Lymph Node–Negative Colorectal Cancer
Hyslop, T., Weinberg, D. S., Schulz, S., Barkun, A. N., & Waldman, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3113 · Cited by 31
Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non–muscle-invasive bladder cancer
Kim, J. H., & Park, J. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.04.020 · Cited by 31
SOX9 expression predicts relapse of stage II colon cancer patients
Espersen, M. L. M., Linnemann, D., Christensen, I. J., Alamili, M., Troelsen, J. T., & Høgdall, E. V. S. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.12.026 · Cited by 31
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
Green, A. R., Soria, D., Powe, D. G., Nolan, C. C., Aleskandarany, M. A., Szász, M. A., Tõkés, A., Ball, G., Garibaldi, J. M., Rakha, E. A., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3804-1 · Cited by 31
Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study
Yu, S. J., Kim, H., Min, H., Sohn, A., Cho, Y. Y., Yoo, J., Lee, D. H., Cho, E. J., Lee, J., Gim, J., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00833 · Cited by 31

Authors: McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
Affiliations: National Institutes of Health (US)
Corresponding author: McShane, Lisa M.
ORCID: McShane, Lisa M.
Altman, Douglas G.
Sauerbrei, Willi
Gion, Massimo
Clark, Gary M.
Venue: JNCI: Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2005-08-17
Volume: 97
Issue: 16
Pages: 1180-1184
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/dji237
OpenAlex: W2096910745
Cited by: 2,162
References: 46
Citations by year: 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
FWCI: 56.89
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: Yale University
Yale Cancer Center
Cancer Research UK
Translational Cancer Research Network
National Cancer Institute (MD 20892, 20892)
Topics: Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
Keywords: tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
MeSH terms: Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks